 JERUSALEM, March 15, 2021 PRNewswire -- Intec Pharma Ltd. NASDAQ: NTEC Intec or the Company announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc., a privately-held, preclinical-stage biotechnology company developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumor and anti-viral immune responses. 